BEAM-302

July 23, 2026: Beam Therapeutics Inc. (NASDAQ: BEAM) announced it will present updated clinical data from its Phase 1/2 trial of BEAM-302, an in vivo liver-targeting base-editing therapy, for severe alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 (Barcelona, Sept. 5–9, 2026). The presentation (“First-in-Human in vivo Gene Editing for Severe AATD: Initial Data from the Phase 1/2 Study of BEAM-302”) is scheduled for Tuesday, Sept. 8, 2026 (9:30–10:45 a.m. CEST), with a company investor conference call/webcast at 7:00 a.m. ET the same day.

BEAM-302 is an LNP formulation designed to correct the SERPINA1 PiZ (E342K) mutation via an A-to-G edit, with the stated aim of reducing toxic Z-AAT, generating corrected M-AAT, and increasing total/functional circulating AAT to address both liver and lung disease. The release notes mutation correction has been durable in treated patients and states the company is preparing to initiate a pivotal cohort.